| Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. | |
| | |
MedLine Citation:
|
PMID: 18833583 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Limited data exist about the role of second-line chemotherapy response assessed by positron emission tomography (PET) as a prognostic factor in patients with aggressive non-Hodgkin Lymphoma (NHL) who undergo autologous stem cell transplantation (ASCT). The objective of this analysis was to investigate the main determinants of prognosis in patients with aggressive B-cell NHL who undergo ASCT, focusing on the impact of pretransplantation PET, secondary age-adjusted International Prognostic Index (sAA-IPI) score, histology, and previous response to first-line chemotherapy. METHODS: Seventy-five patients with diffuse, large B-cell lymphoma or grade 3 follicular lymphoma who were treated at the author' institution with second-line chemotherapy (combined ifosfamide, etoposide, and epirubicin [IEV]) followed by ASCT between September 2002 and September 2006 were included. All patients were evaluated by PET after 1 to 3 courses of IEV chemotherapy before ASCT, and all patients received a conditioning regimen of combined carmustine, etoposide, cytosine arabinoside, and melphalan. The prognostic impact of pretransplantation PET, sAA-IPI score, histology, and previous response to first-line chemotherapy was evaluated by univariate and multivariate analyses. RESULTS: Seventy-two of 75 patients underwent ASCT. In a univariate analysis for progression-free survival (PFS) and overall survival (OS), a significant association was observed with pretransplantation PET (PFS, P< .00001; OS, P< .01) and previous first-line response (PFS, P= .02; OS, P= .04). In the multivariate framework, pretransplantation PET was identified as the only independent prognostic factor (PFS, P< .001; OS, P= .01). CONCLUSIONS: The current data indicated that pretransplantation PET is the main prognostic predictor in patients with aggressive B-cell NHL who are scheduled for ASCT. |
| | |
Authors:
|
Enrico Derenzini; Gerardo Musuraca; Stefano Fanti; Vittorio Stefoni; Monica Tani; Lapo Alinari; Filippo Venturini; Letizia Gandolfi; Michele Baccarani; Pier Luigi Zinzani |
Related Documents
:
|
16314643 - [18f]fluorodeoxyglucose positron emission tomography predicts outcome for ewing sarcoma... 1985763 - Clinical presentation, treatment, and outcome of trilateral retinoblastoma. 9586603 - Metachronous renal cell carcinoma metastasis to the contralateral adrenal gland. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cancer Volume: 113 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 2008 Nov |
Date Detail:
|
Created Date: 2008-10-27 Completed Date: 2008-11-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 2496-503 Citation Subset: AIM; IM |
Affiliation:
|
Institute of Hematology and Medical Oncology L. & A. Seràgnoli, University of Bologna, Bologna, Italy. enrico.derenzini@libero.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Carmustine / administration & dosage Cyclophosphamide / administration & dosage Cytarabine / administration & dosage Etoposide / administration & dosage Female Fluorodeoxyglucose F18 / diagnostic use Hematopoietic Stem Cell Transplantation* Humans Ifosfamide / administration & dosage Lymphoma, Follicular / pathology, radionuclide imaging, therapy Lymphoma, Large B-Cell, Diffuse / pathology, radionuclide imaging*, therapy* Male Melphalan / administration & dosage Middle Aged Positron-Emission Tomography* Predictive Value of Tests Prognosis Prospective Studies Radiopharmaceuticals / diagnostic use Remission Induction Salvage Therapy Survival Analysis Transplantation, Autologous Vincristine / administration & dosage |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 147-94-4/Cytarabine; 148-82-3/Melphalan; 154-93-8/Carmustine; 33419-42-0/Etoposide; 3778-73-2/Ifosfamide; 50-18-0/Cyclophosphamide; 57-22-7/Vincristine; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of preoccupation on interpersonal recall: a pilot study.
Next Document: Down-regulation of Bax-interacting factor-1 in colorectal adenocarcinoma.